MedTrace Logo

AI-Guided Sarcopenia Risk Assessment and Detection

NCT07426159 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-02-23

No results posted yet for this study

Summary

Sarcopenia, the age-related decline in muscle mass and function, is a major contributor to frailty, disability, and mortality in older adults. Current diagnostic tools assess muscle quantity or function separately and lack predictive biomarkers, limiting early detection and personalized management. This study proposes an AI-driven framework that integrates multimodal physiological, metabolic, and functional data with wearable sensor monitoring to improve sarcopenia risk assessment and guide individualized interventions.

In Phase 1, we will analyze a large retrospective dataset of 3,500 adults to identify early predictors of sarcopenia and develop a machine learning-based risk stratification model. Phase 2 will test a 12-week personalized exercise and nutrition intervention in 120 participants, using real-time sensor data and AI-guided adjustments to optimize outcomes. This integrative approach aims to advance early detection, precision intervention, and long-term muscle health in aging populations.

Conditions

Interventions

BEHAVIORAL

Personalized AI-Guided Exercise and Nutrition

Participants complete 12 weeks of supervised resistance and aerobic training combined with personalized nutrition support. Exercise prescriptions (3 resistance sessions/week; 2-3 aerobic sessions/week) and dietary guidance (including protein targets) are individualized using AI models and wearable data. A mobile app provides real-time feedback and monitoring, with biweekly safety check-ins.

Sponsors & Collaborators

  • Tel Aviv University

    lead OTHER

Principal Investigators

  • Yftach Gepner · Tel Aviv University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07426159 on ClinicalTrials.gov